机构:[1]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.[3]Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
National Key Research and
Development Program of China (No. 2018YFC1313201) and the
National Natural Science Foundation of China (No. 81972862).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版:
大类|3 区医学
小类|3 区肿瘤学
第一作者:
第一作者机构:[1]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
通讯作者:
推荐引用方式(GB/T 7714):
Liu Yang,Jia Wenxiao,Li Ji,et al.Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.[J].Frontiers in oncology.2020,10:587343.doi:10.3389/fonc.2020.587343.
APA:
Liu Yang,Jia Wenxiao,Li Ji,Zhu Hui&Yu Jinming.(2020).Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma..Frontiers in oncology,10,
MLA:
Liu Yang,et al."Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.".Frontiers in oncology 10.(2020):587343